ADAR and colorectal carcinoma: Likewise, in the ADAR1-down or ADAR1-up group of CRC patients, 4 out of 6 (67%) or 8 out of 14 (57%) showed ≥ 2-fold decrease or increase in circCHEK2 expression in tumors, respectively (Fig. 6f).